NICE draft guidance recommends siponimod for treating secondary progressive multiple sclerosis



NICE has today (15 October 2020) issued draft guidance which now recommends siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).



Read More


4 views1 comment